{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:19:43Z","timestamp":1791267583706,"version":"4.1.0"},"reference-count":177,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.critrevonc.2015.08.021","type":"journal-article","created":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T18:51:03Z","timestamp":1440787863000},"page":"385-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma"],"prefix":"10.1016","volume":"96","author":[{"given":"Matteo S.","family":"Carlino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Kefford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Rizos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2015.08.021_bib0005","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1172\/JCI65780","article-title":"Melanoma adapts to RAF\/MEK inhibitors through FOXD3-mediated upregulation of ERBB3","volume":"123","author":"Abel","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0010","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/cncr.28620","article-title":"Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors","volume":"120","author":"Ackerman","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0015","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1200\/JCO.2013.50.4118","article-title":"BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1\/2 inhibition","volume":"31","author":"Andrews","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0020","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(12)70413-8","article-title":"Cutaneous toxicities of RAF inhibitors","volume":"14","author":"Anforth","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1479-5876-10-107","article-title":"Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use","volume":"10","author":"Ascierto","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0035","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","article-title":"trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma","volume":"31","author":"Ascierto","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0040","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1200\/JCO.2012.46.1061","article-title":"Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma","volume":"31","author":"Bahadoran","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0045","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0050","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/CMR.0000000000000099","article-title":"Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma","volume":"24","author":"Bowyer","year":"2014","journal-title":"Melanoma Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0055","first-page":"8555","article-title":"BRAF mutation as a pejorative marker in metastatic melanoma","volume":"30","author":"Brissy","year":"2012","journal-title":"ASCO Meet. Abstr."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0060","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1074\/jbc.272.2.1368","article-title":"The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42\/p44MAPK cascade","volume":"272","author":"Brondello","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0065","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/cncr.28864","article-title":"The MAPK pathway across different malignancies: a new perspective","volume":"120","author":"Burotto","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0070","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jamadermatol.2013.8198","article-title":"Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma","volume":"149","author":"Busser","year":"2013","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0075","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1056\/NEJMoa1208958","article-title":"Progression of RAS-mutant leukemia during RAF inhibitor treatment","volume":"367","author":"Callahan","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0080","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1158\/1535-7163.MCT-13-0011","article-title":"Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and\/or MEK inhibition in melanoma","volume":"12","author":"Carlino","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0085","doi-asserted-by":"crossref","first-page":"423","DOI":"10.18632\/oncoscience.51","article-title":"Resistance to c-Kit inhibitors in melanoma: insights for future therapies","volume":"1","author":"Carlino","year":"2014","journal-title":"Oncoscience"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0090","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.molonc.2014.01.003","article-title":"Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma","volume":"8","author":"Carlino","year":"2014","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0095","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/bjc.2014.287","article-title":"Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma","volume":"111","author":"Carlino","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0100","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1200\/JCO.2013.51.5783","article-title":"New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma","volume":"33","author":"Carlino","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/1078-0432.CCR-14-0759","article-title":"Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients","volume":"21","author":"Carlino","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0110","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0115","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1947601911408079","article-title":"RAS interaction with PI3K: more than just another effector pathway","volume":"2","author":"Castellano","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0120","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1002\/cncr.28851","article-title":"The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition","volume":"120","author":"Chan","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0125","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0130","first-page":"3728","article-title":"Mitogen-actived protein kinase activation is an early event in melanoma progression","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"96","key":"10.1016\/j.critrevonc.2015.08.021_bib0135","doi-asserted-by":"crossref","first-page":"196ra98","DOI":"10.1126\/scitranslmed.3005753","article-title":"TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma","volume":"5","author":"Corcoran","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0140","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0145","first-page":"940","article-title":"Switching therapy pre-emptively from vemurafenib (VEM) to ipilimumab (IPI) in patients (pts) with BRAF-mutated melanoma (MEL)","volume":"26","author":"D'Angelo","year":"2013","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0150","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1158\/2159-8290.CD-12-0097","article-title":"BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors","volume":"2","author":"Dahlman","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0155","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature11814","article-title":"Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance","volume":"494","author":"Das","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0160","first-page":"9036","article-title":"Updated overall survival (OS) results for BRF113220, a phase I-II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM)","volume":"33","author":"Daud","year":"2015","journal-title":"ASCO Meet. Abstr."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0165","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0170","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1755-148X.2011.00873.x","article-title":"Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma","volume":"24","author":"Devitt","year":"2011","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0175","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.molcel.2004.11.055","article-title":"Regulation of Raf-1 by direct feedback phosphorylation","volume":"17","author":"Dougherty","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0180","doi-asserted-by":"crossref","first-page":"9483","DOI":"10.1158\/0008-5472.CAN-05-4227","article-title":"In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling","volume":"66","author":"Dumaz","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0185","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1056\/NEJMc1113752","article-title":"Ultraviolet A and photosensitivity during vemurafenib therapy","volume":"366","author":"Dummer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0190","first-page":"9028","article-title":"Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma","volume":"31","author":"Dummer","year":"2013","journal-title":"ASCO Meet. Abstr."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0195","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","article-title":"Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study","volume":"50","author":"Dummer","year":"2014","journal-title":"Eur. J. Cancer."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0200","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1128\/MCB.24.6.2308-2317.2004","article-title":"Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion","volume":"24","author":"Eblen","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0205","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing","volume":"16","author":"Edlundh-Rose","year":"2006","journal-title":"Melanoma Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0210","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/bjd.12504","article-title":"The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort","volume":"169","author":"Ekedahl","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0215","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","article-title":"Clinical correlates of NRAS and BRAF mutations in primary human melanoma","volume":"17","author":"Ellerhorst","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0220","doi-asserted-by":"crossref","first-page":"20411","DOI":"10.1073\/pnas.0905833106","article-title":"MEK1 mutations confer resistance to MEK and B-RAF inhibition","volume":"106","author":"Emery","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0225","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0230","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0235","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0240","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0245","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0250","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0255","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.molcel.2005.10.022","article-title":"Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization","volume":"20","author":"Garnett","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0260","doi-asserted-by":"crossref","unstructured":"Genomic Classification of Cutaneous Melanoma. Cell. 2015;161:1681-96","DOI":"10.1016\/j.cell.2015.05.044"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0265","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","article-title":"GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition","volume":"17","author":"Gilmartin","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0270","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2159-8290.CD-12-0386","article-title":"Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma","volume":"3","author":"Girotti","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0275","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1158\/0008-5472.CAN-14-1392","article-title":"Inhibition of mTORC1\/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1alpha and oxidative phosphorylation in melanoma","volume":"74","author":"Gopal","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0280","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/jid.2012.63","article-title":"Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF\/MEK inhibition","volume":"132","author":"Gowrishankar","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0285","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1158\/1078-0432.CCR-09-0190","article-title":"Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors","volume":"15","author":"Gramza","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0290","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1158\/1535-7163.MCT-11-0989","article-title":"Combinations of BRAF, MEK, and PI3K\/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations","volume":"11","author":"Greger","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0295","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0300","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1755-148X.2010.00685.x","article-title":"PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells","volume":"23","author":"Halaban","year":"2010","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0305","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1158\/1078-0432.CCR-09-0189","article-title":"Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer","volume":"15","author":"Hammerman","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0310","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/ncb867","article-title":"Sprouty1 and Sprouty2 provide a control mechanism for the Ras\/MAPK signalling pathway","volume":"4","author":"Hanafusa","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0315","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","article-title":"Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF","volume":"23","author":"Haq","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0320","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/1541-7786.MCR-13-0581","article-title":"Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma","volume":"12","author":"Hartsough","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0325","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0330","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0335","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0340","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0345","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0350","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0355","doi-asserted-by":"crossref","first-page":"279ra41","DOI":"10.1126\/scitranslmed.aaa4691","article-title":"Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma","volume":"7","author":"Hu-Lieskovan","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0360","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-13-1746","article-title":"BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition","volume":"19","author":"Hutchinson","year":"2013","journal-title":"Clinical Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0365","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0370","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0375","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2014.57.3535","article-title":"Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor","volume":"32","author":"Johnson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0380","first-page":"9008","article-title":"BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms","volume":"33","author":"Johnson","year":"2015","journal-title":"ASCO Meet. Abstr."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0385","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/his.12169","article-title":"Impact of MET expression on outcome in BRAF(V600E\/K) advanced melanoma","volume":"63","author":"Jubb","year":"2013","journal-title":"Histopathology."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0390","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.bbamcr.2007.01.002","article-title":"Regulation of MAPKs by growth factors and receptor tyrosine kinases","volume":"1773","author":"Katz","year":"2007","journal-title":"Biochim Biophys. Acta."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0395","first-page":"965","article-title":"Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicenter study","volume":"26","author":"Kefford","year":"2013","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0400","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","article-title":"Phase II study of the MEK1\/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor","volume":"31","author":"Kim","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0405","doi-asserted-by":"crossref","first-page":"e67583","DOI":"10.1371\/journal.pone.0067583","article-title":"Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF\/MEK tool combination reduced skin lesions","volume":"8","author":"King","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0410","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ejca.2012.11.004","article-title":"BRAF inhibitor activity in V600R metastatic melanoma","volume":"49","author":"Klein","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0415","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/07853890600551037","article-title":"Targeting the ERK signaling pathway in cancer therapy","volume":"38","author":"Kohno","year":"2006","journal-title":"Ann. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0420","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/bj3570297","article-title":"Mitogen-activated protein kinases control p27\/Kip1 expression and growth of human melanoma cells","volume":"357","author":"Kortylewski","year":"2001","journal-title":"Biochem. J."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0425","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0430","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(14)70051-8","article-title":"Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study","volume":"15","author":"Larkin","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0435","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/modpathol.2013.226","article-title":"Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors","volume":"27","author":"Lezcano","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0440","doi-asserted-by":"crossref","first-page":"8125","DOI":"10.1038\/sj.onc.1205034","article-title":"Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development","volume":"20","author":"Li","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0445","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/j.cellsig.2008.08.006","article-title":"ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling","volume":"20","author":"Li","year":"2008","journal-title":"Cell. Signal."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0450","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/ng.3218","article-title":"The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies","volume":"47","author":"Lin","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0455","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccr.2012.10.009","article-title":"Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas","volume":"22","author":"Lito","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0460","doi-asserted-by":"crossref","first-page":"ra17","DOI":"10.1126\/scisignal.2001752","article-title":"Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1\/2 inhibitors in colorectal cancer cells","volume":"4","author":"Little","year":"2011","journal-title":"Sci. Signal."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0465","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.jid.5700632","article-title":"Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma","volume":"127","author":"Liu","year":"2007","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0470","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","article-title":"MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4","volume":"21","author":"Liu","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0475","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0480","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0485","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0490","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/ncomms6694","article-title":"Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma","volume":"5","author":"Long","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0495","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0500","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0505","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1200\/JCO.2013.50.4662","article-title":"Diagnosis and treatment of KIT-mutant metastatic melanoma","volume":"31","author":"Lyle","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0510","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.critrevonc.2014.05.005","article-title":"Nras in melanoma: targeting the undruggable target","volume":"92","author":"Mandala","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0515","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/jid.2012.283","article-title":"BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III Melanoma","volume":"133","author":"Mann","year":"2013","journal-title":"J Invest. Dermatol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0520","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/pcmr.12295","article-title":"Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma","volume":"27","author":"Mar","year":"2014","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0525","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdv255","article-title":"The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV 600","author":"Massi","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0530","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0535","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","author":"Menzies","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0540","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/pcmr.12132","article-title":"Paradoxical oncogenesis: are all BRAF inhibitors equal?","volume":"26","author":"Menzies","year":"2013","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0545","doi-asserted-by":"crossref","DOI":"10.1111\/pcmr.12388","article-title":"Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion","author":"Menzies","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0550","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/annonc\/mdu529","article-title":"Characteristics of pyrexia in BRAFV600E\/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I\/II clinical trial","volume":"26","author":"Menzies","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0555","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1158\/0008-5472.CAN-07-6787","article-title":"Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma","volume":"68","author":"Montagut","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0560","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1245\/s10434-012-2457-5","article-title":"Prognostic value of BRAF(V(6)(0)(0)) mutations in melanoma patients after resection of metastatic lymph nodes","volume":"19","author":"Moreau","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2014.11.018","article-title":"Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF\/MEK Cotargeting but Result in Melanoma Drug Addiction","author":"Moriceau","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0570","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1158\/1078-0432.CCR-13-0827","article-title":"Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)","volume":"19","author":"Nathanson","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0575","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0580","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-13-2625","article-title":"Loss of NF1 in cutaneous Melanoma Is associated with RAS activation and MEK dependence","volume":"74","author":"Nissan","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0585","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.molcel.2008.08.026","article-title":"CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation","volume":"31","author":"Noble","year":"2008","journal-title":"Mol. Cell"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0590","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/sj.bjc.6605714","article-title":"Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy","volume":"102","author":"Paraiso","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0595","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2159-8290.CD-13-0440","article-title":"Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis","volume":"4","author":"Parmenter","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0600","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/pcmr.12293","article-title":"(G12D) NRAS and kinase-dead BRAF cooperate to drive naevogenesis and melanomagenesis","volume":"27","author":"Pedersen","year":"2014","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0605","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molonc.2007.12.003","article-title":"Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site","volume":"1","author":"Platz","year":"2008","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0610","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00280-015-2796-6","article-title":"Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?","volume":"76","author":"Porcelli","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0615","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0620","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0625","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0630","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1470-2045(14)70301-8","article-title":"Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study","volume":"15","author":"Ribas","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0635","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0640","first-page":"3003","article-title":"Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and\/or MEK (trametinib) inhibitors in advanced melanoma","volume":"33","author":"Ribas","year":"2015","journal-title":"ASCO Meet. Abstr."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0645","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","article-title":"BRAF Inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact","volume":"20","author":"Rizos","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0650","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0655","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0660","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0665","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0670","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1158\/1078-0432.CCR-13-0661","article-title":"Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression","volume":"19","author":"Romano","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0675","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3892\/ol.2014.2122","article-title":"Molecular alterations in clinical stage III cutaneous melanoma: correlation with clinicopathological features and patient outcome","volume":"8","author":"Rutkowski","year":"2014","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0680","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1038\/ncomms8103","article-title":"Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing","volume":"6","author":"Salton","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0685","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ejca.2015.03.004","article-title":"Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma","volume":"51","author":"Schadendorf","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0690","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ejca.2015.01.009","article-title":"Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression","volume":"51","author":"Scholtens","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0695","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1038\/sj.onc.1209379","article-title":"Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma","volume":"25","author":"Sensi","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0700","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1158\/0008-5472.CAN-11-0140","article-title":"Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition","volume":"71","author":"Shi","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0705","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1158\/2159-8290.CD-12-0022","article-title":"Preexisting MEK1 exon 3 mutations in V600E\/KBRAF melanomas do not confer resistance to BRAF inhibitors","volume":"2","author":"Shi","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0710","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/ncomms1727","article-title":"Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance","volume":"3","author":"Shi","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0715","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0720","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1158\/2159-8290.CD-13-0279","article-title":"A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0725","first-page":"4514","article-title":"High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer","volume":"61","author":"Simon","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0730","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0735","first-page":"9005","article-title":"BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1\/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM)","volume":"31","author":"Sosman","year":"2013","journal-title":"ASCO Meet. Abstr."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0740","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fgene.2013.00066","article-title":"Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors","volume":"4","author":"Stones","year":"2013","journal-title":"Front. Genet."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0745","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0750","doi-asserted-by":"crossref","first-page":"ra90","DOI":"10.1126\/scisignal.2001212","article-title":"The mammalian MAPK\/ERK pathway exhibits properties of a negative feedback amplifier","volume":"3","author":"Sturm","year":"2010","journal-title":"Sci. Signal."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0755","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0760","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1158\/0008-5472.CAN-11-1875","article-title":"Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation","volume":"72","author":"Su","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0765","first-page":"9007","article-title":"A phase Ib\/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment","volume":"33","author":"Sullivan","year":"2015","journal-title":"ASCO Meet. Abstr."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0770","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0775","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/onc.2012.562","article-title":"The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma","volume":"33","author":"Todd","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0780","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2012.44.7888","article-title":"Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma","volume":"31","author":"Trunzer","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0785","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.1158\/0008-5472.CAN-04-1669","article-title":"SPRY2 is an inhibitor of the ras\/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant","volume":"64","author":"Tsavachidou","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0790","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1371\/journal.pone.0000236","article-title":"B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis","volume":"2","author":"Ugurel","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0795","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Van","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0800","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0805","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0810","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.celrep.2013.08.023","article-title":"Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma","volume":"4","author":"Villanueva","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0815","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1371\/journal.pmed.0050120","article-title":"Improving melanoma classification by integrating genetic and morphologic features","volume":"5","author":"Viros","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0820","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/pcmr.12171","article-title":"Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain","volume":"27","author":"Wagenaar","year":"2014","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0825","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling","volume":"29","author":"Wagle","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0830","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2159-8290.CD-13-0631","article-title":"MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF\/MEK inhibition","volume":"4","author":"Wagle","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0835","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0840","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/jid.2014.418","article-title":"Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas","volume":"135","author":"Wang","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0845","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0850","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1158\/0008-5472.CAN-14-1232-T","article-title":"The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF","volume":"74","author":"Watson","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0855","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0860","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1158\/2159-8290.CD-12-0470","article-title":"A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition","volume":"3","author":"Whittaker","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0865","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1038\/sj.onc.1206443","article-title":"Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival","volume":"22","author":"Widlund","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0870","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1535-7163.MCT-12-0530","article-title":"Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine","volume":"11","author":"Wilmott","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0875","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","article-title":"Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma","volume":"18","author":"Wilmott","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0880","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1128\/MCB.21.9.3192-3205.2001","article-title":"Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway","volume":"21","author":"Woods","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.critrevonc.2015.08.021_bib0885","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","article-title":"Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition","volume":"30","author":"Zimmer","year":"2012","journal-title":"J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815300366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815300366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T19:56:07Z","timestamp":1567108567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842815300366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":177,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1040842815300366"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.08.021","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}